Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Putting the brakes on BTLA in T cell–mediated cancer immunotherapy

4 Jan 2010

Abstract excerpt

Attenuating coinhibitory molecules for the treatment of cancer is gaining a great deal of attention as a strategy for immunotherapy. The B and T lymphocyte attenuator (BTLA, CD272) is a novel coinhibitory molecule structurally and functionally related to CTLA-4 and PD-1. A study in this issue of the JCI by Derré et al. reveals that BTLA is expressed on virus-specific human CD8+ T cells but is progressively...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Immune Cell Function and Interaction
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 20038807
DOI: 10.1172/jci41811

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Putting the brakes on BTLA in T cell–mediated cancer immunotherapyPMID 20038807Read ↗

BET inhibitor in combination with BCG vaccine enhances antitumor efficacy and orchestrates T cell reprogramming for melanomaSemantic proximity Read ↗

New B7 Family Checkpoints in Human CancersSemantic proximity Read ↗

PD-1 and BTLA and CD8<sup>+</sup>T-cell “exhaustion” in cancerSemantic proximity Read ↗

Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter.Semantic proximity Read ↗

Coinhibitory Pathways in Immunotherapy for CancerSemantic proximity Read ↗

The B7 Family and Cancer Therapy: Costimulation and CoinhibitionSemantic proximity Read ↗

Immunotherapies: The Blockade of Inhibitory SignalsSemantic proximity Read ↗

Targeting Cbl-b in cancer immunotherapySemantic proximity Read ↗

Soluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer ImmunotherapySemantic proximity Read ↗

VISTA: A Promising Target for Cancer Immunotherapy?Semantic proximity Read ↗

Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer.Semantic proximity Read ↗

The third group of the B7‐ CD 28 immune checkpoint family: HHLA 2, TMIGD 2, B7x, and B7‐H3Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.